SCHEMBL4497885

SCHEMBL4497885

CCN1C(=O)C(C)(C)c2cc3nc(-c4n[nH]c5cc(C=Cc6cccc([N+](=O)[O-])c6)ccc45)[nH]c3cc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 2/20 0.47
AURKB Q96GD4 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
MAPT P10636 3/20 0.40
LMNA P02545 2/20 0.40
HTT P42858 2/20 0.40
RAB9A P51151 2/20 0.40
MCL1 Q07820 1/20 0.40
PTK2B Q14289 1/20 0.40
CDK2 P24941 2/20 0.37
CHEK1 O14757 1/20 0.37
SRC P12931 1/20 0.37
KDR P35968 1/20 0.37
FLT3 P36888 1/20 0.37
GSK3B P49841 1/20 0.37
MAOB P27338 1/20 0.36
GUSB P08236 1/20 0.35
ALDH1A1 P00352 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4497883 1.00 AURKA (0.47) AURKAAURKBSMN1; SMN2MEN1KMT2A
SCHEMBL4507275 0.90 AURKA (0.51) AURKAAURKBPTK2BCDK2CHEK1
SCHEMBL4507269 0.90 AURKA (0.51) AURKAAURKBPTK2BCDK2CHEK1
SCHEMBL4516787 0.89 AURKA (0.49) AURKAAURKBSMN1; SMN2MEN1KMT2A
SCHEMBL4507234 0.89 AURKA (0.49) AURKAAURKBCDK2CHEK1SRC
SCHEMBL4507231 0.89 AURKA (0.49) AURKAAURKBCDK2CHEK1SRC
SCHEMBL4500983 0.86 AURKA (0.49) AURKAAURKBCDK2CHEK1SRC
SCHEMBL4500978 0.86 AURKA (0.49) AURKAAURKBCDK2CHEK1SRC
SCHEMBL4501399 0.86 AURKA (0.51) AURKAAURKBCDK2CHEK1SRC
SCHEMBL4504808 0.86 AURKA (0.51) AURKAAURKBMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090291968-A1 SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS GEORGES GUY 2009-11-26 US claimed
US-20090291968-A1 SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS GEORGES GUY 2009-11-26 US disclosed
EP-2001882-A1 SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. Hoffmann-La Roche AG (CH) 2008-12-17 EP disclosed
WO-2007107346-A1 SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2007-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291968-A1 SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS CYP3A43, CYP3A5, CYP3A7 AURKA 1558/4885AURKB 2087/4885SMN1; SMN2 4281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.